Swiss supplier will produce HuMax-TF in Slough, UK
Lonza has signed a development and manufacturing agreement with Genmab of Denmark for a novel antibody drug conjugate (ADC), HuMax-TF.
The Swiss pharmaceutical industry supplier will perform process development and cGMP manufacturing for the naked antibody in its Slough, UK facility, followed by cytotoxic drug conjugation to produce HuMax-TF ADC at its facility in Visp, Switzerland.
Financial details of the agreement have not been disclosed.
‘Lonza is pleased to enter into this agreement with Genmab on this novel product that leverages Lonza’s experience in both high potency synthetic chemistry and mammalian biopharmaceutical manufacturing,’ said Stephan Kutzer, chief operating officer of Lonza Custom Manufacturing.
HuMax-TF is a fully human antibody targeted to tissue factor (TF), a protein involved in tumour signalling and angiogenesis. TF is highly expressed on many solid tumours.
HuMax-TF ADC uses technology licensed from Seattle Genetics, a biotechnology company focused on developing antibody-based therapies in Seattle, Washington, US.